Ezt az oldalt automatikusan lefordították, és a fordítás pontossága nem garantált. Kérjük, olvassa el a angol verzió forrásszöveghez.

Vizsgálat a szubkután emicizumab hatékonyságának, biztonságosságának, farmakokinetikájának és farmakodinámiájának értékelésére a születéstől 12 hónapos korig tartó hemofíliában szenvedő betegeknél gátlók nélkül (HAVEN 7)

2026. szeptember 30. frissítette: Hoffmann-La Roche

IIIb fázisú, többközpontú, nyílt, egykarú vizsgálat a szubkután emicizumab hatékonyságának, biztonságosságának, farmakokinetikájának és farmakodinámiájának értékelésére a születéstől 12 hónapos korig tartó hemofíliás A-betegeknél, inhibitorok nélkül

This is a Phase IIIb, multicenter, open-label, single-arm study of prophylactic emicizumab in previously untreated and minimally treated patients at study enrollment from birth to ≤12 months of age with severe hemophilia A (intrinsic factor VIII [FVIII] level <1%) without FVIII inhibitors. The study is designed to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of emicizumab administered at 3 milligrams per kilogram of body weight (mg/kg) once every 2 weeks (Q2W) for 52 weeks. After 1 year of treatment, participants will continue to receive emicizumab (1.5 mg/kg once every week [QW], 3 mg/kg Q2W or 6 mg/kg once every 4 weeks [Q4W]) over a 7-year long-term follow-up period under this study frame.

A tanulmány áttekintése

Állapot

Aktív, nem toborzó

Körülmények

Beavatkozás / kezelés

Tanulmány típusa

Beavatkozó

Beiratkozás (Tényleges)

55

Fázis

  • 3. fázis

Kapcsolatok és helyek

Ez a rész a vizsgálatot végzők elérhetőségeit, valamint a vizsgálat lefolytatásának helyére vonatkozó információkat tartalmazza.

Tanulmányi helyek

      • Vienna, Ausztria, 1090
        • Medizinische Universität Wien
    • New South Wales
      • Westmead, New South Wales, Ausztrália, 2145
        • The Children's Hospital at Westmead
    • Victoria
      • Parkville, Victoria, Ausztrália, 3052
        • Royal Children's Hospital
    • Western Australia
      • Nedlands, Western Australia, Ausztrália, 6009
        • Perth Children's Hospital
      • Brussels, Belgium, 1200
        • Cliniques Universitaires St-Luc
      • Leuven, Belgium, 3000
        • UZ Leuven Gasthuisberg
    • São Paulo
      • Ribeirão Preto, São Paulo, Brazília, 14051-140
        • Hospital das Clínicas Faculdades Médicas de Ribeirão Preto
      • Johannesburg, Dél-Afrika, 2193
        • Charlotte Maxeke Johannesburg Hospital
      • Glasgow, Egyesült Királyság, G51 4TF
        • Queen Elizabeth University Hospital
    • Arizona
      • Phoenix, Arizona, Egyesült Államok, 85016
        • Phoenix Children's Hospital
    • California
      • Los Angeles, California, Egyesült Államok, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, Egyesült Államok, 80045
        • University of Colorado Denver, Children's Hospital
    • Louisiana
      • New Orleans, Louisiana, Egyesült Államok, 70112
        • Tulane University Health Sciences Center
    • Michigan
      • Ann Arbor, Michigan, Egyesült Államok, 48109-0934
        • University of Michigan
    • Washington
      • Seattle, Washington, Egyesült Államok, 98105
        • Seattle Children's Hospital
      • Paris, Franciaország, 75015
        • Groupe Hospitalier Necker Enfants Malades
      • Tel HaShomer, Izrael, 5262100
        • Sheba Medical Center - National Hemophilia Center
    • Ontario
      • Ottawa, Ontario, Kanada, K1H 8L1
        • Children's Hospital of Eastern Ontario
      • Toronto, Ontario, Kanada, M5G 1X8
        • The Hospital for Sick Children
      • Bonn, Németország, 53127
        • Universitätsklinikum Bonn
      • Mörfelden-Walldorf, Németország, 64546
        • Hämophilie-Zentrum Rhein Main GmbH
    • Campania
      • Naples, Campania, Olaszország, 80123
        • AORN Santobono Pausilipon
    • Emilia-Romagna
      • Parma, Emilia-Romagna, Olaszország, 43126
        • AOU di Parma
    • Lombardy
      • Milan, Lombardy, Olaszország, 20122
        • IRCCS Ca' Granda Ospedale Maggiore Policlinico
    • Tuscany
      • Florence, Tuscany, Olaszország, 50134
        • AOU Careggi
      • Madrid, Spanyolország, 28046
        • Hospital Universitario la Paz
      • Seville, Spanyolország, 41013
        • Hospital Universitario Virgen del Rocio
    • Barcelona
      • Esplugues de Llobregat, Barcelona, Spanyolország, 08950
        • Hospital Sant Joan de Deu
      • Adana, Törökország (Türkiye), 01130
        • Adana Acibadem Hospital
      • Ankara, Törökország (Türkiye), 06100
        • Hacettepe University Medical Faculty
      • Izmir, Törökország (Türkiye), 35100
        • Ege University, School of Medicine
      • Samsun, Törökország (Türkiye), 55139
        • Ondokuz Mayis Univ. Med. Fac.

Részvételi kritériumok

A kutatók olyan embereket keresnek, akik megfelelnek egy bizonyos leírásnak, az úgynevezett jogosultsági kritériumoknak. Néhány példa ezekre a kritériumokra a személy általános egészségi állapota vagy a korábbi kezelések.

Jogosultsági kritériumok

Tanulmányozható életkorok

1 másodperc (Gyermek)

Egészséges önkénteseket fogad

Nem

Tanulmányozható nemek

Összes

Leírás

Inclusion Criteria:

  • Age from birth to ≤12 months at time of informed consent
  • Body weight ≥3 kilograms (kg) at time of informed consent. Patients with a lower body weight can be enrolled after they have reached a body weight of 3 kg. Premature babies (gestational age <38 weeks) may be enrolled as long as they have reached a body weight of 3 kg. For premature babies, the corrected gestational age should be reported.
  • Mandatory receipt of vitamin K prophylaxis according to local standard practice
  • Diagnosis of severe congenital hemophilia A (intrinsic FVIII level <1%)
  • A negative test for FVIII inhibitor (i.e., <0.6 Bethesda units [BU]/mL) locally assessed during the 2-week screening period
  • No history of documented FVIII inhibitor (i.e., <0.6 BU/mL), FVIII drug-elimination half-life <6 hours, or FVIII recovery <66%
  • Previously untreated patients or minimally treated patients (i.e., up to 5 days of exposure with hemophilia-related treatments, such as plasma-derived FVIII, recombinant FVIII, fresh frozen plasma, cryoprecipitate, or whole blood products)
  • Documentation of the details of the hemophilia-related treatments received since birth
  • Documentation of the details of the bleeding episodes since birth
  • For patients from birth to <3 months of age at the time of study entry: no evidence of active intracranial hemorrhage, as confirmed by a negative cranial ultrasound at screening irrespective of delivery mode
  • Adequate hematologic, hepatic, and renal function, as defined in the protocol
  • For parents/caregivers: willingness and ability to comply with the study protocol requirements, scheduled visits, treatment plans, laboratory tests, completion of applicable questionnaires, and other study procedures

Exclusion Criteria:

  • Inherited or acquired bleeding disorder other than severe hemophilia A
  • Use of systemic immunomodulators (e.g., interferon) at enrollment or planned use during the study
  • Receipt of any of the following: Prior use of emicizumab prophylaxis including investigational or commercial emicizumab; An investigational drug to treat or reduce the risk of hemophilic bleeds within 5 drug-elimination half-lives of last drug administration; A non-hemophilia-related investigational drug within the last 30 days or 5 drug-elimination half-lives, whichever is shorter; An investigational drug concurrently
  • Current active severe bleed, such as intracranial hemorrhage
  • Planned surgery (excluding minor procedures, e.g., circumcision, CVAD placement) during the study
  • History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection
  • Patients who are at high risk for thrombotic microangiopathy (TMA) (e.g., have a previous medical or family history of TMA, such as thrombotic thrombocytopenic purpura, atypical hemolytic uremic syndrome) in the investigator's judgment
  • Previous or current treatment for thromboembolic disease (with the exception of previous catheter-associated thrombosis in patients for whom anti-thrombotic treatment is not currently ongoing) or signs of thromboembolic disease
  • Any hereditary or acquired maternal condition that may predispose the patient to thrombotic events (e.g., inherited thrombophilias antiphospholipid syndrome)
  • Other diseases (e.g., certain autoimmune diseases) that may increase risk of bleeding or thrombosis
  • Known infection with HIV, hepatitis B virus, or hepatitis C virus
  • Serious infection requiring antibiotics or antiviral treatments within 14 days prior to screening
  • Concurrent disease, treatment, abnormality in clinical laboratory tests, vital signs measurements, or physical examination findings that could interfere with the conduct of the study or that would, in the opinion of the investigator or Sponsor, preclude the patient's safe participation in and completion of the study or interpretation of the study results
  • Unwillingness of the parent or caregiver to allow receipt of blood or blood products, or any standard-of-care treatment for a life-threatening condition
  • Any other medical, social, or other condition that may prevent adequate compliance with the study protocol in the opinion of the investigator

Tanulási terv

Ez a rész a vizsgálati terv részleteit tartalmazza, beleértve a vizsgálat megtervezését és a vizsgálat mérését.

Hogyan készül a tanulmány?

Tervezési részletek

  • Elsődleges cél: Kezelés
  • Kiosztás: N/A
  • Beavatkozó modell: Egyetlen csoportos hozzárendelés
  • Maszkolás: Nincs (Open Label)

Fegyverek és beavatkozások

Résztvevő csoport / kar
Beavatkozás / kezelés
Kísérleti: Emicizumab

Initially, all participants will receive 4 loading doses of 3 milligrams per kilogram (mg/kg) emicizumab subcutaneously (SC) once every week (QW) for 4 weeks followed by the maintenance dosing regimen 3 mg/kg emicizumab SC once every 2 weeks (Q2W) for a total of 52 weeks. Starting from Week 17 of treatment, individual participants may have their dose up-titrated to 3 mg/kg SC QW if they experience suboptimal bleeding control.

At the Week 53 clinic visit following consultation with the treating physician, parents/caregivers may elect for their child to continue with the maintenance 3-mg/kg SC Q2W dosing regimen or to switch to the maintenance 1.5-mg/kg SC QW or 6-mg/kg SC once every 4 weeks (Q4W) dosing regimen for the subsequent 7-year long-term follow-up period.

During the study, participants will be treated with emicizumab until unacceptable toxicity, discontinuation from the study due to any cause, or other criteria specified in the protocol, whichever occurs first.

Más nevek:
  • Hemlibra
  • RO5534262
  • RG6013
  • ACE910

Mit mér a tanulmány?

Elsődleges eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Model-Based Annualized Bleeding Rate for Treated Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated bleed was defined as a bleed that was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for All Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for All Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for All Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of all bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. In this outcome measure, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded. As "all bleeds" comprises both treated and non-treated bleeds, the 72-hour rule was implemented separately for treated and non-treated bleeds. For treated bleeds, the 72-hour rule meant that two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. For non-treated bleeds, the 72-hour rule was implemented by calculating a treatment-free period of 72 hours from the bleed itself.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Spontaneous Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period was estimated as an annualized bleeding rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Spontaneous Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated spontaneous bleeds over the efficacy period is presented here as a calculated annualized bleeding rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated spontaneous bleed was defined as a treated bleed (bleed directly followed by a hemophilia medication reported to be a "treatment for bleed") with no other known contributing factor such as trauma or procedure/surgery. The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Model-Based Annualized Bleeding Rate for Treated Joint Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period was estimated as an annualized bleed rate (ABR) using a negative binomial regression model, which accounts for different follow-up times. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Mean Calculated Annualized Bleeding Rate for Treated Joint Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)
Median Calculated Annualized Bleeding Rate for Treated Joint Bleeds
Időkeret: From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

The number of treated joint bleeds over the efficacy period is presented here as a calculated annualized bleed rate (ABR) that was annualized for each participant using the following formula: ABR = (number of bleeds/number of days during the efficacy period) x 365.25. A treated joint bleed was defined as a bleed with type reported as "joint" based on at least one of the following symptoms: increasing swelling or warmth of the skin over the joint and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline, and the bleed was directly followed by a hemophilia medication reported to be a "treatment for bleed". The 72-hour rule was implemented: two bleeds of the same type and at the same anatomical location were counted as one bleed if the second bleed occurred within 72 hours from the last treatment for the first bleed. Bleeds due to surgery/procedure were excluded.

From first dose of emicizumab to the clinical cutoff date or withdrawal date, whichever was earlier (median [range, min-max] efficacy period: 101.9 [52.6-119.7] weeks)

Másodlagos eredményintézkedések

Eredménymérő
Intézkedés leírása
Időkeret
Az emicizumab plazma mélyponti koncentrációi (Ctrough).
Időkeret: Előadagolás az 1., 3., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. héten
Előadagolás az 1., 3., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. héten
Emicizumab elleni antitestek előfordulása
Időkeret: 1., 5., 17., 29., 41. és 53. hét, majd ezt követően klinikailag indokoltnak megfelelően a vizsgálat befejezéséig (8 évig)
1., 5., 17., 29., 41. és 53. hét, majd ezt követően klinikailag indokoltnak megfelelően a vizsgálat befejezéséig (8 évig)
Hemophilia Joint Health Score (HJHS) teljes pontszám meghatározott időpontokban a hosszú távú követési időszak alatt
Időkeret: A követés 4., 5., 6., 7. és 8. évében
A követés 4., 5., 6., 7. és 8. évében
Mágneses rezonancia képalkotás (MRI) specifikus ízületek pontszáma meghatározott időpontokban a hosszú távú követési időszak alatt
Időkeret: A követés 5. és 8. évében
A követés 5. és 8. évében
A nemkívánatos események előfordulása és súlyossága, a súlyosság meghatározása az Egészségügyi Világszervezet (WHO) toxicitási besorolási skálája szerint
Időkeret: Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Thromboemboliás események előfordulása
Időkeret: Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
A thromboticus mikroangiopátia előfordulása
Időkeret: Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Az injekció beadásának helyén fellépő reakciók előfordulása és súlyossága, a súlyosság meghatározása a WHO toxicitási besorolási skálája szerint
Időkeret: Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Súlyos túlérzékenység, anafilaxia és anafilaktoid események előfordulása
Időkeret: Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
A vizsgálati kábítószer-kezelés abbahagyásához vezető nemkívánatos események előfordulása
Időkeret: Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
Az emicizumab első adagjától a vizsgálat befejezéséig (8 év)
A pulzusszám változása az alapértékhez képest az idő múlásával
Időkeret: Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
A légzésszám változása az alapvonalhoz képest az idő múlásával
Időkeret: Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
A testhőmérséklet változása az alapértékhez képest az idő múlásával
Időkeret: Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
A szisztolés vérnyomás változása az alapértékhez képest az idő múlásával
Időkeret: Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
A diasztolés vérnyomás változása az alapértékhez képest az idő múlásával
Időkeret: Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
Alapállapot, 1., 2., 3., 4., 5., 7., 9., 13., 17., 21., 25., 29., 33., 37., 41., 45., 49. és 53. hét, valamint évente a 7 éves követés során a tanulmányok befejezéséig tartó időszak (legfeljebb 8 év)
Number of Participants According to Hematology and Serum Chemistry Laboratory Test Result Shifts From Baseline WHO Grade to the Highest WHO Grade Post-Baseline
Időkeret: Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53

Laboratory parameters for hematology and blood chemistry were measured at baseline and over time, and the values were compared with a standard reference range. Values outside the standard reference range were considered laboratory abnormalities and graded according to the World Health Organization (WHO) toxicity grading scale, ranging from lowest (Grade 1) to greatest (Grade 4) deviation from standard in the direction indicated for the abnormality (i.e., below (Low) or above (High) the reference range; 'Not Low' and 'Not High' indicate values within the reference range). Participants were categorized according to their laboratory test result shift from baseline WHO grade to highest WHO grade at any point post-baseline (up to Week 53) for each parameter. 'Missing' indicates that the test result was not available.

Baseline, Weeks 4, 13, 21, 29, 37, 45, and 53
Incidence of De Novo Development of Factor VIII Inhibitors
Időkeret: As clinically indicated from baseline until study completion (up to 8 years)

As per the protocol, after any 3 exposure days to FVIII or a block of FVIII exposure days (e.g., a block is defined as a minimum of two consecutive doses of FVIII) administered for treatment of a bleed, a surgical procedure, or other (e.g., preventative doses before activity), one plasma sample for anti-FVIII antibodies (for centralized analysis) had to be collected 14 days after the final dose of FVIII administered.

As clinically indicated from baseline until study completion (up to 8 years)

Együttműködők és nyomozók

Itt találhatja meg a tanulmányban érintett személyeket és szervezeteket.

Nyomozók

  • Tanulmányi igazgató: Clinical Trials, Hoffmann-La Roche

Publikációk és hasznos linkek

A vizsgálattal kapcsolatos információk beviteléért felelős személy önkéntesen bocsátja rendelkezésre ezeket a kiadványokat. Ezek bármiről szólhatnak, ami a tanulmányhoz kapcsolódik.

Tanulmányi rekorddátumok

Ezek a dátumok nyomon követik a ClinicalTrials.gov webhelyre benyújtott vizsgálati rekordok és összefoglaló eredmények benyújtásának folyamatát. A vizsgálati feljegyzéseket és a jelentett eredményeket a Nemzeti Orvostudományi Könyvtár (NLM) felülvizsgálja, hogy megbizonyosodjon arról, hogy megfelelnek-e az adott minőség-ellenőrzési szabványoknak, mielőtt közzéteszik őket a nyilvános weboldalon.

Tanulmány főbb dátumok

Tanulmány kezdete (Tényleges)

2021. február 4.

Elsődleges befejezés (Tényleges)

2023. május 22.

A tanulmány befejezése (Becsült)

2030. május 18.

Tanulmányi regisztráció dátumai

Először benyújtva

2020. június 11.

Először nyújtották be, amely megfelel a minőségbiztosítási kritériumoknak

2020. június 11.

Első közzététel (Tényleges)

2020. június 16.

Tanulmányi rekordok frissítései

Utolsó frissítés közzétéve (Tényleges)

2026. október 1.

Az utolsó frissítés elküldve, amely megfelel a minőségbiztosítási kritériumoknak

2026. szeptember 30.

Utolsó ellenőrzés

2026. szeptember 1.

Több információ

A tanulmányhoz kapcsolódó kifejezések

Egyéb vizsgálati azonosító számok

  • MO41787
  • 2020-001733-12 (EudraCT szám)
  • 2023-505964-13-00 (Registry Identifier: EU CT Number)
  • 2023 (Az Egyesült Államok NIH támogatása/szerződése)

Terv az egyéni résztvevői adatokhoz (IPD)

Tervezi megosztani az egyéni résztvevői adatokat (IPD)?

IGEN

IPD terv leírása

For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

Gyógyszer- és eszközinformációk, tanulmányi dokumentumok

Egy amerikai FDA által szabályozott gyógyszerkészítményt tanulmányoz

Igen

Egy amerikai FDA által szabályozott eszközterméket tanulmányoz

Nem

Ezt az információt közvetlenül a clinicaltrials.gov webhelyről szereztük be, változtatás nélkül. Ha bármilyen kérése van vizsgálati adatainak módosítására, eltávolítására vagy frissítésére, kérjük, írjon a következő címre: register@clinicaltrials.gov. Amint a változás bevezetésre kerül a clinicaltrials.gov oldalon, ez a webhelyünkön is automatikusan frissül. .

Iratkozz fel